NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Diagnostics & Research · USD

Charles River Laboratories International, Inc. (CRL) Stock Analysis

Charles River Laboratories International, Inc. (CRL) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.

CRL

$288.50

−$4.85 (−1.65%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRL with… →

CRL Key Statistics

As of Sep 4, 2026
Trading
Open
$288.29
Previous Close
$293.35
Day's Range
285.34–291.69
52-Week Range
144.26–303.31
Volume
738.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.41
Valuation
Market Cap
$13.90B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
22.74
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.12
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.47
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.81
Financials (FY)
Revenue (FY)
$4.02B−0.85%
Net Income (FY)
−$144.34M−1501.75%
Profit marginThe share of revenue left as profit after all costs and taxes.
−5.96%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.17M
1-Year Return
+77.75%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
893.41K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CRL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+44.63%
2025+8.06%
2024−21.91%
2023+8.49%
2022−42.17%
2021+50.80%
2020+63.56%
2019+34.97%
2018+3.41%
2017+43.65%
2016 (partial year)−9.65%

As of September 4, 2026.

CRL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.02B−$144.34M−3.6%
2024$4.05B$10.30M0.3%
2023$4.13B$474.62M11.5%
2022$3.98B$486.23M12.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.02B$1.32B$401.14M−$144.34M−3.6%
2024$4.05B$1.33B$442.35M$10.30M0.3%
2023$4.13B$1.50B$617.26M$474.62M11.5%
2022$3.98B$1.46B$650.98M$486.23M12.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRL Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricCRLDiagnostics & Research medianvs median
P/S ratio3.474.9930% below
Profit margin−5.96%0.00%6.0 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Charles River Laboratories International, Inc. (CRL) is capitalised at $13.90B on the latest close. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 18,300 employees.

The 52-week range on file runs from $144.26 to $303.31. The most recent close on file for CRL is $288.50, dated September 4, 2026. That is −$4.85 (−1.65%) against the previous close. The latest close sits 99.99% above that 52-week low.

Financial Health

In fiscal 2025, Charles River Laboratories International, Inc. reported revenue of $4.02B. That is −0.85% against the prior fiscal year, when revenue was $4.05B. The same year closed with a net loss of $144.34M. The reported profit margin is −5.96%. That is 6 percentage points below the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to −4.81.

Across the 4 fiscal years on file, revenue moves from $3.98B in 2022 to $4.02B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 22.74. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.12. The price-to-sales ratio is 3.47. On price-to-sales that is 30.37% below the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

The reported beta is 1.41. Daily returns over the trailing 10 years annualize to a volatility of 38.2%. The trailing one-year price return is +77.75%. Across 10 years the annualized return works out at +13.08%.

Growth & Income

No dividend is on file for CRL.

Across the complete calendar years on file, 2020 returned +63.56% and 2022 returned −42.17%. Of the 9 complete calendar years on file, 7 finished higher. So far in 2026 the price is +44.63%.

Peer Comparison

Charles River Laboratories International, Inc. (CRL) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Charles River Laboratories International, Inc. CRL $13.90B —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Charles River Laboratories International, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Visit website →